Heidelberg Pharma AG

M&A Activity • Apr 30, 2014

News Details

Ad-hoc | 30 April 2014 12:32

WILEX AG: WILEX and IBA terminate marketing partnership – Global rights to REDECTANE(R) diagnostic agent revert to WILEX

WILEX AG / Key word(s): Agreement

30.04.2014 12:32

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

WILEX and IBA terminate marketing partnership - Global rights to
REDECTANE(R) diagnostic agent revert to WILEX

Munich, 30 April 2014. WILEX AG (ISIN DE0006614720 / WL6 / FSE) and IBA
Pharma SPRL (IBA S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB),
Louvain-la-Neuve, Belgium, today agreed to terminate their licence
agreement for REDECTANE(R) signed in 2008 and retransfer all rights granted
to IBA under the licence agreement with immediate effect to WILEX,
particularly the exclusive licence granted for the production and global
marketing of REDECTANE(R).

IBA will make all marketing, development and regulatory data collected
under this partnership available to WILEX and will support WILEX in
transferring the technology to a potential new manufacturer or marketing
partner. IBA will also reimburse costs to WILEX AG.

WILEX now is in a position to contact new partners for the external
development, financing, production and marketing of REDECTANE(R).

---

Information and Explaination of the Issuer to this News:

About REDECTANE(R)
REDECTANE(R) (INN: 124I-Girentuximab) is a radiolabelled form of the
antibody Girentuximab, which binds to the antigen CAIX on clear cell renal
cell carcinoma. The antibody-based radiopharmaceutical REDECTANE(R) could
support physicians in diagnosing renal cancers. Determining that no clear
cell renal cell cancer is present constitutes an important goal. This could
fundamentally change therapy planning for renal cancer patients and avoid
potentially unnecessary surgery. Furthermore, REDECTANE(R) may also prove
suitable for monitoring response to treatment and for diagnosing other
kinds of tumours. The Phase III REDECT trial completed in 2010 showed that
REDECTANE(R) can differentiate between clear cell and non-clear cell renal
cell cancer and that PET/CT with REDECTANE(R) was clearly superior to CT.

In recent months, WILEX has drawn up the development strategy and trial
design for the confirmatory Phase III trial (REDECT 2), for which it
received a special protocol assessment (SPA) from the FDA in the fourth
quarter of 2013. WILEX AG will no longer conduct the REDECT 2 trial, but
aims to arrange the financing, development and commercialisation for
REDECTANE(R) externally.

About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates based on antibodies and small molecules, which are available for
out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical
contract research services and an antibody drug conjugate (ADC) technology
platform. Our customers and partners include leading international
pharmaceutical companies. WILEX is listed at the Frankfurt Stock Exchange:
ISIN DE0006614720 / WKN 661472 / Symbol WL6. More information is available
at www.wilex.com

Contact For press enquiries
WILEX AG MC Services AG
Corporate Communications Katja Arnold (CIRO)
Sylvia Wimmer Tel.: +49 (0)89-41 31 38-126
Tel.: +49 (0)89-41 31 38-29 Tel.: +49-89-210 228-40
Email: investors[at]wilex.com Mobil: +49 160 9360 3022
Grillparzerstr. 10, 81675 Munich, E-Mail: katja.arnold[at]mc-
Germany services.eu

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

30.04.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---